Intuitive Surgical, Inc. $ISRG Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 95.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 2,105,544 shares of the medical equipment provider’s stock after buying an additional 1,027,475 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Intuitive Surgical were worth $970,635,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. raised its position in shares of Intuitive Surgical by 300.0% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 33 shares during the period. Olistico Wealth LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $28,000. Main Street Group LTD acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $30,000. Laurel Wealth Advisors LLC purchased a new position in shares of Intuitive Surgical in the 4th quarter valued at about $31,000. Finally, Vermillion Wealth Management Inc. grew its holdings in Intuitive Surgical by 58.1% in the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 25 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the subject of several research analyst reports. Sanford C. Bernstein reduced their target price on Intuitive Surgical from $750.00 to $685.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. TD Cowen dropped their price target on shares of Intuitive Surgical from $585.00 to $520.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a report on Monday. Truist Financial reduced their price objective on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Finally, BTIG Research decreased their price objective on shares of Intuitive Surgical from $512.00 to $469.00 and set a “buy” rating on the stock in a report on Friday, July 17th. Twenty-one analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $523.46.

Insider Buying and Selling

In related news, Director Amy L. Ladd sold 119 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total value of $55,156.50. Following the sale, the director directly owned 120 shares in the company, valued at approximately $55,620. The trade was a 49.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the transaction, the senior vice president directly owned 6,463 shares in the company, valued at $2,718,014.65. The trade was a 46.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 7,169 shares of company stock valued at $3,059,135. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $332.02 on Friday. The company’s 50-day moving average is $408.55 and its two-hundred day moving average is $460.85. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The firm has a market capitalization of $117.30 billion, a price-to-earnings ratio of 38.03, a PEG ratio of 2.47 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the previous year, the company earned $1.81 EPS. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.84 earnings per share for the current fiscal year.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive outlined its AI-enabled future for surgical care, including a five-layer AI framework and real-time telesurgical collaboration, reinforcing its innovation pipeline and potential to deepen its competitive moat. Intuitive Shares Vision for an AI-Enabled Future of Healthcare
• Positive Sentiment: Analyst coverage continues to view ISRG as an attractive long-term MedTech growth name, citing the expanding robotic surgery ecosystem and innovation pipeline. ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?
• Positive Sentiment: CONMED expanded AirSeal robotic compatibility for the da Vinci 5 hex cannula, which supports broader adoption of Intuitive’s newest system. CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
• Neutral Sentiment: Multiple analyst roundups reiterated that Wall Street generally still rates ISRG favorably, but these reports were largely commentary rather than new fundamental catalysts. Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?
• Neutral Sentiment: Recent coverage also emphasized that Intuitive remains a premium valuation story, with valuation support coming from margins, AI software, and international growth, but with slower U.S. procedure growth creating uncertainty. Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
• Negative Sentiment: J&J’s entry into U.S. robotic surgery increased concerns that da Vinci’s dominance could face real competition, helping pressure sentiment toward ISRG. J&J enters US robotic surgery market after device gets marketing authorization
• Negative Sentiment: Analysts have also trimmed fair value estimates and growth assumptions, citing slower procedure growth and broader MedTech multiple compression, which reinforces concerns that upside may be more limited near term. Intuitive Surgical (ISRG) Stock Sees Fair Value Cut As Analysts Trim Growth Views

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.